Antimicrobial susceptibility monitoring of canine and feline skin and ear pathogens isolated from European veterinary clinics: results of the ComPath Surveillance programme

2020 ◽  
Vol 31 (6) ◽  
pp. 431
Author(s):  
Anno Jong ◽  
Myriam Youala ◽  
Farid El Garch ◽  
Shabbir Simjee ◽  
Markus Rose ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Surveillance Programme

scholarly journals Australian Meningococcal Surveillance Programme Annual Report, 2020

2021 ◽  
Vol 45 ◽  
Author(s):  
Monica M Lahra ◽  
CR Robert George ◽  
Masoud Shoushtari ◽  
Tiffany R Hogan
Keyword(s):  
Nucleic Acid ◽  
Antimicrobial Susceptibility ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
Annual Report ◽  
Bacterial Culture ◽  
Sequence Type ◽  
Nucleic Acid Amplification ◽  
Notifiable Disease ◽  
Surveillance Programme

Invasive meningococcal disease (IMD) is a notifiable disease in Australia, and both probable and laboratory-confirmed cases of IMD are reported to the National Notifiable Diseases Surveillance System (NNDSS). In 2020, there were 90 notifications of IMD, the lowest number documented since records began in the NNDSS in 1991. Of these, 97% (87/90) were laboratory-confirmed cases, with 70% (61/87) confirmed by bacterial culture and 30% (26/87) by nucleic acid amplification testing. The serogroup was determined for 85/87 laboratory-confirmed cases of IMD: serogroup B (MenB) accounted for 64% of infections (54/85); MenW for 19% (16/85); MenY for 16% (14/85); and MenC 1.2% (1/85). Fine typing was available on 60/85 (71%) of cases with serogroup determined; of the typed MenW, all were PorA antigen type P1.5,2 and sequence type 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas. The primary peaks of IMD notifications in Australia in 2020 were observed in infants less than 1 year (16/87, 18%) and in adults aged 45–64 years (14/87, 16%). MenB infections predominated in those aged less than 5 years and 15–19 years; MenW and MenY infections predominated in those aged 45 years or more. All 61 IMD isolates were tested for antimicrobial susceptibility: none were penicillin resistant; however, 56/61 (92%) had decreased susceptibility to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.

scholarly journals Australian Meningococcal Surveillance Programme annual report, 2018

2020 ◽  
Vol 44 ◽  
Author(s):  
Monica M Lahra ◽  
Rodney Enriquez ◽  
Tiffany Hogan ◽  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Meningococcal Disease ◽  
Surveillance System ◽  
Annual Report ◽  
Sequence Type ◽  
Molecular Methods ◽  
Invasive Meningococcal Disease ◽  
Notifiable Disease ◽  
Surveillance Programme ◽  
Notifiable Diseases

Invasive meningococcal disease (IMD) is a notifiable disease in Australia, and both probable and laboratory-confirmed cases of IMD are reported to the National Notifiable Diseases Surveillance System (NNDSS). In 2018, there were 281 IMD cases notified to the NNDSS. Of these, 278 were laboratory-confirmed cases analysed by the reference laboratories of the Australian National Neisseria Network (NNN). On investigation, the serogroup was able to be determined for 98.6% (274/278) of laboratory-confirmed cases. Serogroup B infections accounted for 44.2% of cases (123 cases); serogroup W for 36.3% of cases (101 cases); serogroup Y infections for 15.8% (44 cases) and serogroup C 1.4% (4 cases); and there were two unrelated cases (0.7%) of IMD attributable to serogroup E. Using molecular methods, 181/278 IMD cases were able to be typed. Of note was that 89% of typed serogroup W IMD cases (66/74) were porA antigen type P1.5,2; of this number, 44% (29/66) were sequence type 11, the hypervirulent strain reported in recent outbreaks in Australia and overseas. The primary age peak of IMD in Australia in 2018 was again observed in adults aged 45 years or more; a secondary disease peak was observed in children and infants aged less than 5 years. Serogroup B infections predominated in those aged less than 5 years, whereas serogroup W and serogroup Y infections predominated in those aged 45 years or more. Of the IMD isolates tested for antimicrobial susceptibility, 1.4% (3/210) were resistant to penicillin with an MIC ≥ 1 mg/L, and decreased susceptibility to penicillin was observed in a further 93.8% (197/210) of isolates. All isolates were susceptible to ceftriaxone and rifampicin; there was one isolate less susceptible to ciprofloxacin.

scholarly journals Australian Meningococcal Surveillance Programme annual report, 2017

2019 ◽  
Vol 43 ◽  
Author(s):  
Monica M Lahra ◽  
Rodney Enriquez ◽  
CR Robert George
Keyword(s):  
South America ◽  
Antimicrobial Susceptibility ◽  
Molecular Typing ◽  
Surveillance System ◽  
Annual Report ◽  
Sequence Type ◽  
Age Group ◽  
Surveillance Programme ◽  
Encoding Gene ◽  
The Uk

In 2017, there were 374 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the Australian National Neisseria Network. This was the highest number of laboratory-confirmed cases since 2003. Probable and confirmed cases of IMD are notifiable in Australia; there were 379 IMD cases notified to the National Notifiable Diseases Surveillance System in 2017, the highest number reported since 2005. Meningococcal sero-grouping was determined for 98% (367/374) of laboratory-confirmed IMD cases. Serogroup B infections accounted for 137 cases (37%). The number of serogroup W infections (141 cases, 38%) in 2017 was the highest since the Australian Meningococcal Surveillance Programme (AMSP) began. In addition, the number and proportion of serogroup Y infections (75 cases, 20%) was also the highest recorded by the AMSP. Molecular typing results were available for 315 of the 374 IMD cases (83%). Of the serogroup W IMD strains that were able to be genotyped, 97% (125/129) had the PorA antigen encoding gene type P1.5,2 and of these, 59% (74/125) were sequence type 11, the same type as the hypervirulent serogroup W strain that has been circulating in the UK and South America since 2009. The primary IMD age peak was observed in adults aged 45 years or more, whilst secondary disease peaks were observed in those aged less than 5 years. Serogroup B infections predominated in the age group 15–19 years. Serogroup W infections predominated in those aged 65 years or more. Serogroup Y infections were predominately seen in adults aged 45 years or more. Of the IMD isolates tested for antimicrobial susceptibility, 5.1% (14/276) were resistant to penicillin; decreased susceptibility to penicillin was observed in a further 89% (247/276) of isolates. All isolates tested were susceptible to ceftriaxone; two isolates were less susceptible to ciprofloxacin; and one isolate was resistant to rifampicin.

scholarly journals Large increase in ciprofloxacin resistant gonorrhoea in England and Wales

2003 ◽  
Vol 7 (16) ◽  
Author(s):  
Elizabeth Rudd ◽  
K. A. Fenton
Keyword(s):  
Antimicrobial Susceptibility ◽  
Surveillance Programme ◽  
England And Wales ◽  
Preliminary Results ◽  
Minimum Inhibitory Concentrations ◽  
Genitourinary Medicine

Preliminary results from the 2002 collection of the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) (1, 2) show marked increases in resistance to ciprofloxacin in England and Wales. Between June and August 2002, consecutive gonococcal isolates from 26 genitourinary medicine (GUM) clinics were systematically tested for antimicrobial susceptibility at one of two central reference laboratories. The minimum inhibitory concentrations (MICs) of five antimicrobials were determined, including ciprofloxacin (range tested 0.002-0.125 mg/l,) extended to 32 mg/l as necessary). Clinical, demographic, and behavioural data were obtained for each patient included in the collection.

Sign in / Sign up

Export Citation Format

Share Document